Time needed to dissolve gout urate deposits when uric acid is kept very low
Time Required to Dissolve Urate Deposits in Patients With Gout
This project tests whether keeping blood uric acid under 40 mg/L in people with gout will dissolve joint urate deposits and how long that takes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT06669000 on ClinicalTrials.gov |
What this trial studies
ReViGore40 will enroll adults with newly diagnosed gout who are not yet on urate-lowering therapy and who have ultrasound evidence of urate deposits. All participants will start xanthine oxidase inhibitors or uricosurics as appropriate and have their serum urate titrated to a target below 40 mg/L. Ultrasound of feet and knees will be performed every six months and an ultrasound score (0–24) will be used to define complete dissolution as two consecutive scores of 0 six months apart. The study will also collect clinical, biological and genetic data, perform DECT in tophaceous patients, provide patients with home urate meters, and bank blood samples for omics and epigenetic analyses.
Who should consider this trial
Good fit: Adults with gout by 2015 ACR/EULAR criteria, serum urate >60 mg/L, an ultrasound score ≥2/24, not currently on urate-lowering therapy, and able to be followed at the study center are ideal candidates.
Not a fit: People already taking urate-lowering therapy, those with uncontrolled severe illnesses, pregnant or breastfeeding women, or those without French national social security are unlikely to benefit from joining this cohort.
Why it matters
Potential benefit: If successful, the results could show that a strict urate target speeds reliable dissolution of crystals and helps guide treatment toward remission.
How similar studies have performed: Previous work shows lowering serum urate can dissolve crystals and induce remission, but prospectively measuring time to complete dissolution at a strict <40 mg/L target with regular ultrasound is relatively new.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 years * Gout according to the ACR/Eular 2015 criteria * SUA levels greater than 60 mg/L * US score (MTP1s, knees) ≥2/24 * Informed consent Dated and signed voluntarily Exclusion Criteria: * Ongoing urate lowering therapy * Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases * Pregnant or breast-feeding women * No affiliation to the French National Social Security System
Where this trial is running
Paris
- APHP, Lariboisière Hospital, Rheumatology departement — Paris, France (Recruiting)
Study contacts
- Study coordinator: Pascal RICHETTE, PR
- Email: pascal.richette@aphp.fr
- Phone: 0149956314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.